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Abstract
We evaluated BRCA1 and BRCA2 oncosuppressor protein expression in 26 milk samples in women just after delivery. The
quantification of BRCA1 and BRCA2 proteins was performed in isolated milk fat globules using an affinity chromatography
strategy. The amounts of BRCA1 and BRCA2 proteins were found to be similar. We explained the presence of BRCA1 and
BRCA2 proteins in human milk fat globules by the fact that they are formed by exocytosis of lipids from epithelial cells of the
mammary gland and are enveloped by plasma membrane from the apical part of the milk-secreting cells. This raises the
possibility that BRCA1 and BRCA2 proteins are a protective response to proliferation and play a possible role in newborn
nutrition. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Current evidence strongly supports a role for the
breast cancer susceptibility genes, BRCA1 and
BRCA2, in both normal development and carcino-
genesis. A main characteristic of the in vivo pattern
of BRCA1 and BRCA2 expression is that these tu-
mor suppressor genes are expressed at maximal levels
in rapidly proliferating cells. This is well illustrated
during mammary gland development wherein the ex-
pression of BRCA1 and BRCA2 is induced in rapidly
proliferating cellular compartments undergoing dif-
ferentiation, such as terminal end buds during pub-
erty and developing alveoli during pregnancy [1]. In
situ hybridization performed on the mammary
glands of mice revealed that Brca1 and Brca2
mRNA levels are both markedly upregulated early
in pregnancy, a period during which alveolar buds
begin the process of rapid proliferation and di¡er-
entiation to form mature, milk-producing alveoli
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[2^5]. This upregulation of Brca1 and Brca2 expres-
sion occurs preferentially in developing alveoli as
compared with adjacent epithelial ducts, consistent
with patterns of proliferation [3,6]. These authors
have also reported in mice, that Brca1 and Brca2
expression levels decline late in pregnancy, reaching
their lowest point during lactation and early postlac-
tational regression, though expression levels remain
above background even during these stages of devel-
opment [1^5]. Following these results, we investi-
gated the quanti¢cation of BRCA1 and BRCA2 ex-
pression in milk fat globules in women just after
delivery.
2. Materials and methods
2.1. Patients
Twenty-six women were delivered of live-born in-
fants of 37^42 completed weeks’ gestation between
3 April 2000 and 29 June 2000. Milk samples (10 ml)
ranging from day 2 to day 9 after delivery were col-
lected with a breast pump.
2.2. Isolation of human milk fat globules
Human milk fat globules (HMFG) were isolated
according to modi¢ed methods [7,8]. Fresh human
milk was centrifuged at 10 000Ug for 30 min. The
cream, which £oated to the top of the tube, was
recovered and suspended in 0.01 M Tris^HCl bu¡er,
pH 7.5, containing 1 mM MgCl2 and 0.28 M su-
crose. After homogenization, this suspension was re-
centrifuged at 10 000Ug for 30 min, and the washed
cream (i.e. the HMFG) was resuspended in 0.05 M
Tris^HCl bu¡er, pH 7.5 for 1 h at room tempera-
ture. A centrifugation at 10 000Ug for 30 min was
e¡ected. HMFG were suspended in ice-cold 0.02 M
Tris^HCl bu¡er, pH 8, containing 1 mM phenyl-
methylsulfonyl £uoride (PMSF) and 0.5% Nonidet
P-40. The sample was sonicated for 30 s. After 1 h
incubation in ice, a centrifugation was done at
20 000Ug for 45 min at 4‡C. The supernatant con-
taining the solubilized HMFG proteins was removed
and clari¢ed again with a centrifugation at 20 000Ug
for 30 min at 4‡C to eliminate the remaining triglyc-
erides.
2.3. Quanti¢cation of BRCA1 and BRCA2 proteins
Proteins were radioiodinated with 125I according to
the lactoperoxidase procedure [9]. To the removed
particulate matter (1 ml) were added lactoperoxidase
(50 Wg/ml), glucose oxidase (25 Wg/ml) and 0.5 mCi
of 125I. The reaction was set o¡ by adding D-glucose
(250 Wg/ml). After 10 min at room temperature, the
reaction was stopped by adding tyrosine (20 Wg/ml).
The labeled proteins of the supernatant were sepa-
rated from the nonreactant iodide by gel ¢ltration on
a Sephadex G-25 column (Pharmacia Biotech). Elu-
tion was performed with phosphate bu¡ered saline
(PBS). The radioactivity of each eluted fraction (0.5
ml) was measured in a crystal Q-counter (Packard,
Meriden, CT, USA). Eluted fractions with the high-
est radioactivity obtained in the front of the elution
were pooled for subsequent quanti¢cation of BRCA1
or BRCA2 oncosuppressor proteins.
Then, the previously pooled fractions were poured
onto a POROS 20 HE (heparin) column (PerSeptive
Biosystems, Framingham, MA, USA) which is
known to have a great a⁄nity for DNA-binding pro-
teins and BRCA1 and BRCA2 oncosuppressors be-
long to them. Labeled DNA-binding proteins specif-
ically bound to the gel were eluted with a gradient of
NaCl from 0.1 to 1 M in 20 mM MES pH 5.5. The
£ow rate was 5 ml/min with a Biocad Sprint high-
performance liquid chromatography system (PerSep-
tive Biosystems) equipped with a fraction collector
(Gilson, Middelton, WI, USA). Detection of proteins
was performed at 280 nm. The 0.5 ml fractions con-
taining DNA-binding proteins were collected, the ra-
dioactivity was measured in a crystal Q-counter and
pooled. The collected sample was divided into two
equal parts. In one part, radiolabeled BRCA2 pro-
teins were immunoprecipitated with a 30 min incu-
bation at 37‡C, by the addition of 5 Wg of anti-
BRCA2 polyclonal antibodies (66076E, Pharmingen,
San Diego, CA, USA), which recognizes epitopes
between amino acids 2586 and 2600 of human
BRCA2. In the other part, radiolabeled BRCA1 pro-
teins were immunoprecipitated with anti-BRCA1
polyclonal antibodies (66036E, Pharmingen), which
recognize epitopes between amino acids 2 and 20 of
human BRCA1.
The two immune complexes (BRCA1/anti-BRCA1
antibodies and BRCA2/anti-BRCA2 antibodies)
BBADIS 62070 18-12-01
C. Vissac et al. / Biochimica et Biophysica Acta 1586 (2002) 50^56 51
were isolated separately by chromatography onto
POROS A containing protein A medium. Elution
was performed with 0.1% (v/v) 12 mM HCl/0.15 M
NaCl, pH 2 (£ow rate 5 ml/min with a Biocad Sprint
HPLC system). Detection of the immune complex
was performed at 280 nm. The radioactivity of
each fraction was measured as described below. Pro-
tein A a⁄nity chromatography by means of immune
complex elution gave the amount of DNA-binding
proteins that bind speci¢cally to anti-BRCA1 or
anti-BRCA2 antibodies, and the ratio was calculated
as follows: (activity (dpm) of BRCA1 or BRCA2
DNA-binding proteins that bound speci¢cally to
the anti-BRCA1 or anti-BRCA2 antibodies/activity
(dpm) of whole labeled DNA-binding proteins eluted
from heparin column)U100 [10].
2.4. Statistical analysis
All data are the means þ S.D. of all experiments.
All statistical analyses were performed using Stu-
dent’s t-test. One-tailed P values 6 0.05 were consid-
ered statistically signi¢cant.
2.5. Western blot analysis
HBL 100 cells (1U107) were lysed in 1 ml of lysis
bu¡er (20 mM Tris^HCl, pH 8, 137 mM NaCl, 1%
Triton X-100, 10% glycerol, 5 mM EDTA, 1 mM
sodium orthovanadate, 1 mM PMSF, leupeptin 10
Wg/ml, aprotinin 10 Wg/ml, 1 mM NaF), sonicated
for 30 s and kept at 4‡C for 30 min, then centrifu-
gation was performed at 12 000Ug for 3 min and the
supernatant was collected. Protein assay was per-
formed (Bio-Rad, Munich, Germany). One hundred
and ¢fty micrograms of lysate were denatured for 10
min in 200 Wl of Laemmli’s bu¡er 2U (100 mM Tris^
HCl pH 6.8, 200 mM dithiothreitol, 0.4% sodium
dodecyl sulfate (SDS), 0.2% bromophenol blue,
20% glycerol) at 55‡C for BRCA2 [11] and 90‡C
for BRCA1, separated by 5% SDS^PAGE.
For Western experiments, the electrophoresed pro-
teins were transferred to Immobilon-P membranes
(Millipore, Bedford, MA, USA), 2 h at room temper-
ature. After incubation for 1 h in blocking bu¡er
(PBS, 0.1% Tween, 5% dry milk), the membranes
were probed for 2 h by the addition of the anti-
BRCA1 (66036E) (0.5 Wg/ml) or anti-BRCA2
(66076E) (4 Wg/ml) primary antibody, followed by
three washings of 10 min in PBS, 0.1% Tween. The
membrane was then incubated for 1 h with peroxi-
dase-conjugated second antibody (anti-IgG-HRP,
Santa Cruz Biotechnologies, Santa Cruz, CA, USA)
(0.2 Wg/ml) in PBS, 0.1% Tween, 1% dry milk,
washed three times for 15 min in PBS, 0.1% Tween,
followed by developing with an enhanced chemilumi-
nescence mixture (Western blotting luminol reagent,
sc-2048; Santa Cruz Biotechnologies) and exposed to
Amersham Hyper¢lm ECL ¢lm.
2.6. Competition with the relevant antigenic peptide
The competition level was also evaluated by PO-
ROS a⁄nity chromatography, as described previ-
ously for BRCA1 and BRCA2 protein determina-
tion. After isolation of DNA-binding proteins by
a⁄nity chromatography on a POROS 20 HE col-
umn, radioactive fractions were separated into two
equal parts. To one part were added 5 Wg of anti-
BRCA1 polyclonal antibodies (66036E), raised
against amino acids 2^20 of human BRCA1, or
anti-BRCA2 polyclonal antibodies (66076E) elicited
against amino acids 2586^2600 of human BRCA2,
and after incubation, the immune complex was iso-
lated on a POROS A column. To the other part were
respectively added anti-BRCA1 polyclonal antibod-
ies previously incubated for 1 h with 10 Wg of a
synthetic peptide corresponding to amino acids 1^
100 of human BRCA1 (sc:4255; Santa Cruz Biotech-
nologies) or anti-BRCA2 polyclonal antibodies pre-
viously incubated for 1 h with 5 mg of the relevant
peptide corresponding to amino acids 2586^2600 of
human BRCA2 protein (Genosphere Biotechnolo-
gies, Paris, France). Quanti¢cation of the immune
complex was performed. Elution pro¢les obtained
in the presence or absence of peptide for these two
antibodies were plotted on a chart to evaluate the
displacement of the equilibrium.
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3. Results
3.1. Characterization of anti-BRCA1 and
anti-BRCA2 antibodies in HBL 100 by
Western blot analysis
To examine the speci¢city of the used anti-BRCA1
and anti-BRCA2 antibodies, HBL 100 protein ex-
tracts were used for the determination of the human
BRCA1 and BRCA2 proteins by Western blotting
(Fig. 1). The rabbit polyclonal antibodies (66036E)
which may predominantly recognize the amino-ter-
minus of human BRCA1 protein were used to probe
the blots and they were able to recognize the 220
kDa BRCA1 form in a breast carcinoma cell line
(HBL 100). The rabbit polyclonal antibodies
(66076E) which may recognize the central portion
of BRCA2 were used to probe the blots with a mam-
mary carcinoma cell lines (HBL 100) and the human
BRCA2 protein was detected at 384 kDa.
Nevertheless, for these two polyclonal antibodies
no cross-reaction was seen with other proteins.
3.2. Quanti¢cation of BRCA1 and BRCA2 proteins in
milk fat globules
Using a quantitative method, we detected in
HMFG among 26 fresh milk samples an amount of
BRCA1 protein of 1.87 þ 0.93% and an amount of
BRCA2 of 1.65 þ 0.88%. These results are expressed
in Fig. 2. The di¡erence between the BRCA1 and
BRCA2 levels was not signi¢cant (P = 0.4).
3.3. Displacement of the equilibrium with the
relevant antigenic peptide
By displacement of the equilibrium with the rele-
vant antigenic peptide during immune complex for-
mation, we demonstrated the speci¢city of the reac-
Fig. 3. Equilibrium displacement of the immune complex by a
synthetic peptide (amino acids 1^100 of BRCA1) with anti-
BRCA1 (66036E) antibodies elicited against amino acids 2^20
of BRCA1.
Fig. 2. Amount of BRCA1 and BRCA2 proteins found in hu-
man milk fat globules isolated from 26 women’s fresh milk col-
lected from day 2 to day 9 after delivery. On the y-axis, the
amounts of BRCA1 and BRCA2 obtained after a protein A
POROS column are expressed as a percentage, i.e. the ratio of
the amount of labeled DNA-binding proteins that bound specif-
ically to the polyclonal antibodies raised against BRCA1 or
BRCA2 to the amount of total labeled DNA-binding proteins
puri¢ed on a heparin POROS column. The di¡erence between
the BRCA1 and BRCA2 levels was not statistically signi¢cant
(P = 0.4, Student’s t-test).
Fig. 1. Expression of BRCA1 and BRCA2 proteins in a breast
tumor cell line (HBL 100). One hundred and ¢fty micrograms
of proteins were analyzed by SDS^PAGE, transfered and
probed respectively with antibodies (Abs) against BRCA1
(66036E) and BRCA2 (66076E) as primary antibody and subse-
quently with HRP-labeled secondary antibody.
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tion due to the anti-BRCA1 polyclonal antibody
66036E by competition assay with the synthetic pep-
tide corresponding to amino acids 1^100 of human
BRCA1 (Fig. 3). In Fig. 4, we demonstrate the dis-
placement of the equilibrium corresponding to
BRCA2 antigens and anti-BRCA2 polyclonal anti-
body 66076E by the synthetic peptide corresponding
to epitopes between 2586 and 2600 of human
BRCA2 used as immunogen [12].
4. Discussion
The staining speci¢cities of 66036E antibodies to
BRCA1 and 66076E antibodies to BRCA2 were as-
certained by Western blotting, a 220 kDa band and a
384 kDa band, respectively, being detected for the
HBL 100 breast cell line.
We have carried out the quanti¢cation of BRCA1
or BRCA2 proteins from cell extract by a strategy of
a⁄nity chromatography. The linearity and reproduc-
ibility of this quanti¢cation have been previously
tested for measuring class II HLA antigen amounts
[13,14]. This quanti¢cation was lately adapted to
BRCA1 glycoproteins [15,16]. Now, we used a new
faster method with perfusion chromatography. Two
successive a⁄nity chromatographies were used: (i) a
heparin a⁄nity column for the ¢rst puri¢cation of all
DNA-binding proteins from cell extract because
BRCA1 and BRCA2 proteins possess a ring ¢nger
and are implicated in transcription [17,18], (ii) a pro-
tein A a⁄nity column, just after immunoprecipita-
tion with anti-BRCA1 or anti-BRCA2 antibodies
to quantify speci¢cally BRCA1 or BRCA2 proteins
from all the puri¢ed DNA-binding proteins previ-
ously obtained [10,19].
Furthermore, the speci¢city of this procedure for
BRCA1 and BRCA2 oncosuppressor protein puri¢-
cation has been veri¢ed here by using respective rel-
evant antigenic peptides added during the formation
of the immune complex (35S-BRCA1 proteins/anti-
BRCA1 antibodies (66036E) or 35S-BRCA2 pro-
teins/anti-BRCA2 antibodies (66076E)) in MCF7
cells. So, we demonstrated the displacement of the
respective immune complex equilibrium during elu-
tion on a protein A POROS column.
Therefore, the patterns of BRCA1 and BRCA2
expression are similar. This can be explained by the
fact that these proteins may function in a common
pathway of tumor suppression [20].
In addition, we previously reported the presence of
BRCA1 and BRCA2 proteins by immunohistochem-
istry in HMFG [21]. These analyses were performed
on two mammary gland samples collected from chil-
dren who respectively died suddenly at the age of
4 weeks, when the mammary gland is active after
birth and may continue to grow and secretes milk,
and at the age of 5 months, when newborn breast
development and milk secretion begin to regress [22],
and in a lactating hamartoma of the breast from an
8 month pregnant woman. Using several antibodies
elicited against BRCA1 and BRCA2, we reported
that ducts of lobules in the mammary gland of the
young child of 4 weeks contained milk secretion with
BRCA1 and BRCA2 expression in the cytoplasm of
HMFG as well as the lactating hamartoma of the
breast. In contrast, tissue sections of the older child’s
mammary gland, at the age of 5 months when milk
secretion has stopped, were devoid of HMFG ex-
pressing BRCA1 and BRCA2 proteins.
In women, we explained the presence of BRCA1
and BRCA2 proteins in these HMFG by the fact
that they are formed by exocytosis of lipids from
epithelial cells of the mammary gland, and are envel-
oped by plasma membrane from the apical part of
the milk-secreting cells [23]. Similarly, this hypothesis
might explain the presence of BRCA1 and BRCA2
proteins in the HMFG of the secreted milk. Thus,
HMFG provide an excellent source of easily acces-
sible material, including BRCA1 and BRCA2 pro-
teins, from the mammary gland epithelial cells.
These interesting observations are in agreement
Fig. 4. Equilibrium displacement of the immune complex by a
synthetic peptide (amino acids 2586^2600 of BRCA2) used to
produce anti-BRCA2 (66076E) antibodies.
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with our previous results and demonstrated the pres-
ence of BRCA1 and BRCA2 proteins in the human
milk collected from women 2^9 days after delivery.
This raises the possibility that the induction of
BRCA1 and BRCA2 expression is a protective re-
sponse to proliferation and addresses the question
of the possible role of BRCA1 and BRCA2 in new-
born nutrition.
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